Pathstone Holdings
HAE icon

Pathstone Holdings’s Haemonetics HAE Stock Holding History

Pathstone Holdings’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,123
Closed -$251K – 2343
2024
Q3 		$251K Sell
3,123
-25
-0.8% -$2.02K ﹤0.01% 2070
2024
Q2 		$260K Buy
3,148
+657
+26% +$57.8K ﹤0.01% 2019
2024
Q1 		$213K Sell
2,491
-733
-23% -$57.5K ﹤0.01% 2112
2023
Q4 		$276K Buy
+3,224
New +$279K ﹤0.01% 1885

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Pathstone Holdings's HAE Position: Q4 2024 in Review

Pathstone Holdings sold out of Haemonetics (HAE) in Q4 2024, closing a stake of 3,123 shares — an estimated $251K sold.

Pathstone Holdings first reported a position in HAE in Q4 2023 and held it in 4 quarters. The position peaked at $276K in Q4 2023. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

  • Pathstone Holdings reported no remaining Haemonetics position as of Q4 2024 after selling out during the quarter.
  • Pathstone Holdings sold 3,123 Haemonetics shares in Q4 2024, an estimated $251K.
  • Pathstone Holdings first reported a position in Haemonetics in Q4 2023 and held it in 4 quarters.
  • Pathstone Holdings's Haemonetics position peaked at $276K in Q4 2023.
  • 309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on Pathstone Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.